Clinical trials: Other Bacterial Diseases
COVID-19, Viral Pneumonia
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19.
- Conditions
- COVID-19, Viral Pneumonia, Pneumonia Due to Streptococcus Pneumoniae, Bacterial Pneumonia
- Trial name
- PROVID-CAPNETZ (NCT04952337)
- Where
- 15 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Hannover Medical School
Bacterial Skin Diseases
Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia
Approximately 3,000 of clinically significant isolates of different species from respective respective sources in geographically distinct Russian cities will be collected and tested on ceftaroline and other antimicrobials.
- Trial name
- CERBERUS (NCT01700842)
- Where
- 2 sites in Russia
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Haemophilus Infections, Diphtheria
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.
- Conditions
- Haemophilus Infections, Diphtheria, Tetanus, Polio
- Trial name
- NCT00855855
- Testing
- DTaP-IPV/Hib
- Where
- 59 sites in United States
- Volunteers
- 20,830 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Invasive Fungal Disease
Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
This study is a post-approval commitment study, and is designed to further evaluate the safety and efficacy of isavuconazole in a relatively larger Chinese population who will receive isavuconazole treatment in a post-marketing…
- Trial name
- NCT05630976
- Testing
- Isavuconazole
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Pfizer
Bacterial Diseases, Other Mycoses
Reducing Vaginal Infections in Women
The purpose of this study is to see if taking medication once a month can help to decrease the risk of vaginal infections. Additionally, researchers will study whether personal habits, such as douching, bathing, and sexual…
- Conditions
- Bacterial Diseases, Other Mycoses, Sexually Transmitted Infection
- Trial name
- NCT00170430
- Testing
- Fluconazole, Metronizadole
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Washington
Shock Hypovolemic, Shock, Septic
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths.
- Conditions
- Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline
- Trial name
- NCT04750070
- Testing
- Blood and Dopamine, Blood and adrenaline
- Where
- Bangladesh
- Volunteers
- 135 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Bacteremia, Pseudomonas Infections
Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)
More than 80 patients at the University of Pittsburgh Medical Center have been infected with Pseudomonas aeruginosa, lacking susceptibility to all commercially available antibiotics except "colistin".
- Trial name
- NCT00235690
- Testing
- Blood draws, Blood draw
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Advanced Chronic Liver Disease, Urinary Infection
The INFECIR-2 Albumin Prevention Study
The aim of this study is to evaluate whether albumin administration improves short-term survival in patients with advanced cirrhosis and bacterial infections other than Spontaneous Bacterial Peritonitis (SBP).
- Conditions
- Advanced Chronic Liver Disease, Urinary Infection, Pneumonia, Cholangitis
- Trial name
- INFECIR2 (NCT02034279)
- Testing
- Albumin
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- EASL - CLIF Consortium
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Acute Bacterial Skin and Skin Structure Infection
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI
The aim of this study is to collect the data on the effectiveness of dalbavancin in terms of save of hospitalization days on patients treated between June 2017 and June 2019 in two countries (Italy and Greece) vs the other…
- Trial name
- REDS (NCT04298463)
- Testing
- Xydalba, vancomycin, teicoplanin or daptomycin
- Where
- 16 sites in Greece, Italy
- Volunteers
- 184 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Keratitis Bacterial, Keratitis Fungal
Validation of Interleukins and Other Cytokines Together With OCT Imaging for Rapid Infectious Keratitis Assessment
As conventional corneal scraping with bacterial culturing has several disadvantages such as long duration until diagnosis, invasiveness and lacks alternatives, there is demand for a novel non-invasive, rapid test in keratitis…
- Trial name
- VICTORIA (NCT05620264)
- Testing
- Tear Sample Probe
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Johannes Kepler University of Linz
Nontuberculous Mycobacterial Infections
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
- Trial name
- NCT03164291
- Testing
- Rifabutin
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- The University of Texas Health Science Center at Tyler
Acute Leukemias of Ambiguous Lineage, Bacterial Infection
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant.
- Conditions
- Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection
- Trial name
- NCT01371656
- Testing
- levofloxacin
- Where
- 84 sites in United States, Canada
- Volunteers
- 624 people
- Sponsor
- Children's Oncology Group
Candidiasis
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the…
- Trial name
- NCT00056368
- Testing
- Anidulafungin, Fluconazole
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Pfizer
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Fungus Disease
Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients
This study will collect data on the incidence (rate of occurrence) of fungal infections in recipients of bone marrow, stem cell or organ transplants.
- Trial name
- NCT00026767
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- National Cancer Institute (NCI)
Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
- Trial name
- NCT00802854
- Where
- 10 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Pfizer
Cystic Fibrosis
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and…
- Trial name
- NCT02113397
- Testing
- TOBI™ Podhaler™ 112 mg inhaled twice daily, Colistimethate 75 mg inhaled two times daily
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dartmouth-Hitchcock Medical Center